Additional file 2: of Biobanking in Israel 2016–17; expressed perceptions versus real life enrollment

Updated consent form and additional information as used in real-life recruitment study. (DOCX 31 kb

Additional file 1: of Biobanking in Israel 2016–17; expressed perceptions versus real life enrollment

Original consent form, as presented to focus group participants. (DOCX 17 kb

Additional file 1: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

A comprehensive summary of sample sizes and cohorts in pharmacogenetics studies in the field of multiple sclerosis. (DOCX 23 kb

Additional file 12: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Details on participating institutional or clinical sites at which Institutional Review Boards or Ethics Committees approved the clinical trials included in the study. (DOCX 59 kb

Additional file 3: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Table S3. Transcription factor enrichment analysis of genes differentially expressed in the mouse striatum. (XLSX 18 kb

Additional file 5: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Table S5. Pathway analysis of alternatively spliced genes identified after high dose treatment with pridopidine. (XLSX 31 kb

Additional file 4: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Table S4. qPCR validation of striatal gene expression identified in RNAseq and pathway analysis. (XLSX 10 kb

Additional file 1: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Table S1. Adjusted p-val range and fold change range for differential expression and DUEJ genes meeting adj p-val < 0.05 cutoff. (XLSX 11 kb

<i>APOE</i> allele frequencies by ‘523’ genotypes in different ethnicities in the US.

<p><i>APOE</i> allele frequencies by ‘523’ genotypes in different ethnicities in the US.</p

‘523’ Allele frequencies in non US geographical cohorts (Far Eastern and West Africa).

<p>Genotypes determination was performed by Polymorphic, Inc. using a sequencing based assay.</p